Machine Learning Identifies CHAF1A In Burkitt Lymphoma

CHROMATIN assembly factor 1 subunit A (CHAF1A) has emerged as a candidate biomarker and potential therapeutic target in Burkitt lymphoma (BL), following an integrated gene-expression and machine-learning analysis.

Study Identifies Candidate Biomarkers

Researchers combined differential gene expression analysis with Random Forest machine learning to identify and prioritise potential biomarkers and therapeutic targets in BL. The analysis used Gene Expression Omnibus datasets GSE43677 and GSE12453, comparing BL with control cohorts.

Four candidate genes were identified through this approach. The researchers then assessed the leading candidates at the protein level using immunohistochemistry in an independent cohort comprising 10 patients with BL and 10 controls with reactive lymphoid hyperplasia (RLH).

Of the four candidates, only CHAF1A demonstrated pronounced protein-level overexpression in BL tumours compared with RLH controls.

CHAF1A Shows Immune Associations

The researchers subsequently investigated whether CHAF1A expression was associated with immune-cell infiltration. A CIBERSORT analysis conducted using a single dataset identified exploratory correlations between CHAF1A expression and several immune-cell fractions.

The strongest observed association was a positive correlation with M0 macrophages (Pearson r = 0.92, p < 0.001). However, these computational findings were considered hypothesis-generating and did not establish that CHAF1A has a mechanistic role in the tumour immune microenvironment.

The results therefore provided an initial indication that CHAF1A expression may be associated not only with BL but also with differences in immune-cell composition.

Findings Require Functional Validation

The study identified CHAF1A as a candidate biomarker associated with BL and highlighted its potential as a therapeutic target. The combination of transcriptomic analysis, machine learning and independent immunohistochemical validation provided a strategy for prioritising candidates from complex molecular datasets.

Nevertheless, the immune-cell findings were derived from a single-dataset analysis and were exploratory. The observed correlations cannot establish causation or demonstrate a functional role for CHAF1A in BL biology or the tumour immune microenvironment.

Further functional validation will therefore be needed to determine whether CHAF1A contributes to disease development or immune interactions and whether it could ultimately represent a viable therapeutic target.

Reference

Lin W et al. CHAF1A identified as a candidate biomarker and potential therapeutic target in Burkitt lymphoma through integrated bioinformatics and histopathological analysis. Hematology. 2026;31(1):DOI: https://doi.org/10.1080/16078454.2026.2708536.

Featured image: JR-50 on Adobe Stock.